NLS
January 15, 2017
[aas_zone zone_id=”7913″]
Published: January 15, 2017
Top stories
Financing – May 22, 2026
The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap.
Collaboration – May 20, 2026
Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region’s life science development.
Clinical Trials – May 20, 2026
Oncopeptides’ clinical trial application for the “Window-of-Opportunity” (WoO) study in glioblastoma has been formally approved in Norway.
New Market – May 20, 2026
The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.
Related posts
Advertising free banner - January 15, 2017
[aas_zone zone_id=”8010″]
[aas_zone zone_id=”7909″]
[aas_zone zone_id=”7910″]
[aas_zone zone_id=”7915″]
This site uses cookies
Read more about our privacy policy
The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.
The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.
The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.